Ionis Pharmaceuticals Stock Investor Sentiment
| IONS Stock | USD 35.73 0.17 0.47% |
Slightly above 56% of Ionis Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Ionis Pharmaceuticals suggests that many traders are alarmed. Ionis Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Ionis Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Panic Vs Confidence
44
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Ionis Pharmaceuticals' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Ionis Pharmaceuticals.
News SentimentBullish | Hype SentimentBearish | Insider SentimentDisposing |
Ionis Historical Sentiment
Although Ionis Pharmaceuticals' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Ionis, such as negative comments on social media and news outlets, may cause fear in the market and push Ionis Pharmaceuticals' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Ionis.
Ionis |
Ionis Pharmaceuticals Historical Investor Sentiment
Investor biases related to Ionis Pharmaceuticals' public news can be used to forecast risks associated with an investment in Ionis. The trend in average sentiment can be used to explain how an investor holding Ionis can time the market purely based on public headlines and social activities around Ionis Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Ionis Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Ionis Pharmaceuticals and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Ionis Pharmaceuticals news discussions. The higher the estimate score, the more favorable the investor's outlook on Ionis Pharmaceuticals.
Far too much social signal, news, headlines, and media speculation about Ionis Pharmaceuticals that are available to investors today. That information is available publicly through Ionis media outlets and privately through word of mouth or via Ionis internal channels. However, regardless of the origin, that massive amount of Ionis data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Ionis Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Ionis Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Ionis Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Ionis Pharmaceuticals alpha.
Ionis Pharmaceuticals Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Disposition of 4677 shares by Herman Joan E of Ionis Pharmaceuticals subject to Rule 16b-3 | 09/06/2024 |
2 | Insider Trading | 09/27/2024 |
3 | New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA | 10/08/2024 |
4 | Acquisition by Devers Shannon L. of 11280 shares of Ionis Pharmaceuticals subject to Rule 16b-3 | 10/15/2024 |
5 | Disposition of tradable shares by Eric Swayze of Ionis Pharmaceuticals at 38.313 subject to Rule 16b-3 | 10/16/2024 |
6 | Ionis Pharmaceuticals Q3 2024 Earnings Preview | 11/05/2024 |
7 | Ionis Pharmaceuticals, Inc. Q3 2024 Earnings Call Transcript | 11/08/2024 |
8 | Disposition of 13508 shares by Loscalzo Joseph of Ionis Pharmaceuticals at 37.861 subject to Rule 16b-3 | 11/14/2024 |
9 | Ionis Pharmaceuticals, Inc. CEO Brett P. Monia Sells 6,630 Shares | 11/15/2024 |
10 | LLY Oral Cholesterol Drug Lowers Lipoprotein Levels in Phase II Study | 11/19/2024 |
11 | Disposition of 1070 shares by Klein Joseph Iii of Ionis Pharmaceuticals at 42.5473 subject to Rule 16b-3 | 11/20/2024 |
12 | Why Is Ionis Pharmaceuticals, Inc. Among the Worst Performing Biotech Stocks in 2024 | 11/21/2024 |
13 | Ionis Pharmaceuticals Upgraded to Buy What Does It Mean for the Stock | 11/27/2024 |
Additional Tools for Ionis Stock Analysis
When running Ionis Pharmaceuticals' price analysis, check to measure Ionis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ionis Pharmaceuticals is operating at the current time. Most of Ionis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ionis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ionis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ionis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.